Immix Biopharma, Inc.

Immix Biopharma, Inc.Immix Biopharma, Inc.
Immix Biopharma, Inc.

Immix Biopharma, Inc.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Website
DR 33Active53Los Angeles, United States
Rate
Advertise here

About

Immix Biopharma is a biopharmaceutical company developing a revolutionary one-time CAR-T therapy, NXC-201, designed to re-engineer the immune system to fight AL Amyloidosis. This therapy targets diseased cells, aiming to normalize disease within days and provide a durable response with minimal side effects, particularly for vulnerable patients with heart involvement. Immix Biopharma is focused on creating medicines that are both effective and safe, addressing the critical unmet need for relapsed/refractory AL amyloidosis patients.
HEADCOUNT
53
DOMAIN RATING
33
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Immix Biopharma, Inc. do?

Immix Biopharma is a biopharmaceutical company developing a revolutionary one-time CAR-T therapy, NXC-201, designed to re-engineer the immune system to fight AL Amyloidosis. This therapy targets diseased cells, aiming to normalize disease within days and provide a durable response with minimal side effects, particularly for vulnerable patients with heart involvement. Immix Biopharma is focused on creating medicines that are both effective and safe, addressing the critical unmet need for relapsed…

How much funding has Immix Biopharma, Inc. raised?

Immix Biopharma, Inc. has raised a total of $5M in funding. The most recent round on record is At-The-Market Equity Offering.

Where is Immix Biopharma, Inc. headquartered?

Immix Biopharma, Inc. is headquartered in Los Angeles, United States.

What industry does Immix Biopharma, Inc. operate in?

Immix Biopharma, Inc. operates in Biotechnology, Pharmaceuticals, Healthcare, Biotech, MedTech, HealthTech.

How many employees does Immix Biopharma, Inc. have?

Immix Biopharma, Inc. has approximately 53 people on record.

What is Immix Biopharma, Inc.'s revenue?

StartupHub estimates Immix Biopharma, Inc.'s annual revenue at $5.4M (range $2.9M to $15.9M, 69% confidence), based on comparable companies in the sector.

What is Immix Biopharma, Inc.'s valuation?

StartupHub estimates Immix Biopharma, Inc.'s effective valuation at $20.0M (range $12.5M to $30.0M, 12% confidence), based on comparable companies in the sector.